2014 San Antonio Breast Cancer Symposium
Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in p...
Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment ...
Hope S. Rugo, MD, on the Phase II FIRST Study
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from...
Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women wi...
Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast ...
Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary ...
Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer
Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract PD2-1, “The effect on overall and disease-free survival by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemoth...
Clifford A. Hudis, MD, FACP, on the SOFT Trial
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxi...
Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on patholo...
Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and ...
Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer
Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but...
Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen rece...
Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial
Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxife...
Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer
Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented...
Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive B...
Gunter von Minckwitz, MD, on the Phase III ICE Trial
Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04, "The phase III ICE study: Adjuvant ibandronate with or without capecitabine in elderly patients with mo...
Jack Cuzick, PhD, on the IBIS-I Trial
Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."
William M. Sikov, MD, on the CALGB 40603 Trial
William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative ...
Lisa A. Carey, MD, on the TNT Trial
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with me...
Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer
Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast c...
Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss: The TNT trial comparing docetaxel to carboplatin The C...
Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data
Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials: • B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab• B-51, on rad...
William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials
William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.
Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therapeutics for endocrine therapy-resistan...
Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures
Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conser...
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
